دورية أكاديمية
أعرض في EDS

Synthetic BSA-conjugated disaccharide related to the Streptococcus pneumoniae serotype 3 capsular polysaccharide increases IL-17A Levels, γδ T cells, and B1 cells in mice.

التفاصيل البيبلوغرافية
العنوان: Synthetic BSA-conjugated disaccharide related to the Streptococcus pneumoniae serotype 3 capsular polysaccharide increases IL-17A Levels, γδ T cells, and B1 cells in mice.
المؤلفون: Akhmatova NK; Laboratory of Therapeutic Vaccines, Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia., Kurbatova EA; Laboratory of Therapeutic Vaccines, Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia., Zaytsev AE; Laboratory of Therapeutic Vaccines, Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia., Akhmatova EA; Laboratory of Glycoconjugate Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Moscow, Russia., Yastrebova NE; Laboratory of Therapeutic Vaccines, Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia., Sukhova EV; Laboratory of Glycoconjugate Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Moscow, Russia., Yashunsky DV; Laboratory of Glycoconjugate Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Moscow, Russia., Tsvetkov YE; Laboratory of Glycoconjugate Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Moscow, Russia., Nifantiev NE; Laboratory of Glycoconjugate Chemistry, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Moscow, Russia.
المصدر: Frontiers in immunology [Front Immunol] 2024 May 22; Vol. 15, pp. 1388721. Date of Electronic Publication: 2024 May 22 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: Interleukin-17*/immunology , Interleukin-17*/metabolism , Streptococcus pneumoniae*/immunology , Serum Albumin, Bovine*/immunology , Pneumococcal Vaccines*/immunology, Animals ; Mice ; Pneumococcal Infections/immunology ; Pneumococcal Infections/prevention & control ; Disaccharides/immunology ; Bacterial Capsules/immunology ; Polysaccharides, Bacterial/immunology ; Adjuvants, Immunologic/administration & dosage ; Female ; Antibodies, Bacterial/blood ; Antibodies, Bacterial/immunology ; Intraepithelial Lymphocytes/immunology ; Serogroup ; Receptors, Antigen, T-Cell, gamma-delta/immunology ; Receptors, Antigen, T-Cell, gamma-delta/metabolism
مستخلص: The disaccharide (β-D-glucopyranosyluronic acid)-(1→4)-β-D-glucopyranoside represents a repeating unit of the capsular polysaccharide of Streptococcus pneumoniae serotype 3. A conjugate of the disaccharide with BSA (di-BSA conjugate) adjuvanted with aluminum hydroxide induced - in contrast to the non-adjuvanted conjugate - IgG1 antibody production and protected mice against S. pneumoniae serotype 3 infection after intraperitoneal prime-boost immunization. Adjuvanted and non-adjuvanted conjugates induced production of Th1 (IFNγ, TNFα); Th2 (IL-5, IL-13); Th17 (IL-17A), Th1/Th17 (IL-22), and Th2/Th17 cytokines (IL-21) after immunization. The concentration of cytokines in mice sera was higher in response to the adjuvanted conjugate, with the highest level of IL-17A production after the prime and boost immunizations. In contrast, the non-adjuvanted conjugate elicited only weak production of IL-17A, which gradually decreased after the second immunization. After boost immunization of mice with the adjuvanted di-BSA conjugate, there was a significant increase in the number of CD45+/CD19+ B cells, TCR+ γδ T cell, CD5+ В1 cells, and activated cells with MHC II+ expression in the spleens of the mice. IL-17A, TCR+ γδ T cells, and CD5+ В1 cells play a crucial role in preventing pneumococcal infection, but can also contribute to autoimmune diseases. Immunization with the adjuvanted and non-adjuvanted di-BSA conjugate did not elicit autoantibodies against double-stranded DNA targeting cell nuclei in mice. Thus, the molecular and cellular markers associated with antibody production and protective activity in response to immunization with the di-BSA conjugate adjuvanted with aluminum hydroxide are IL-17A, TCR+ γδ T cells, and CD5+ В1 cells against the background of increasing MHC II+ expression.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Akhmatova, Kurbatova, Zaytsev, Akhmatova, Yastrebova, Sukhova, Yashunsky, Tsvetkov and Nifantiev.)
References: Nature. 1988 Sep 29;335(6189):443-5. (PMID: 2458531)
Clin Vaccine Immunol. 2011 May;18(5):724-9. (PMID: 21450979)
Nat Rev Microbiol. 2008 Apr;6(4):288-301. (PMID: 18340341)
Vaccine. 1995 Oct;13(14):1263-76. (PMID: 8585280)
Clin Infect Dis. 2010 Sep 15;51(6):692-9. (PMID: 20715907)
Front Immunol. 2016 Jun 24;7:248. (PMID: 27446078)
Vaccine. 2014 May 1;32(21):2399-405. (PMID: 24637174)
Semin Immunol. 1989 Sep;1(1):55-63. (PMID: 15630959)
Immunity. 2009 Aug 21;31(2):321-30. (PMID: 19682928)
Vaccine. 2007 Mar 1;25(11):1962-8. (PMID: 17258357)
J Infect Dis. 2014 Aug 1;210(3):493-503. (PMID: 24577508)
Eur J Immunol. 1993 Jan;23(1):12-6. (PMID: 7678221)
Paediatr Drugs. 2013 Oct;15(5):403-23. (PMID: 24030738)
Beilstein J Org Chem. 2016 Jul 12;12:1440-6. (PMID: 27559395)
Hum Vaccin. 2008 Jan-Feb;4(1):54-9. (PMID: 18441530)
Angew Chem Int Ed Engl. 2017 Nov 6;56(45):13973-13978. (PMID: 28815890)
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1055-1078. (PMID: 37902243)
Microbiology (Reading). 2006 Feb;152(Pt 2):285-293. (PMID: 16436416)
Immunity. 2005 Jul;23(1):7-18. (PMID: 16039575)
Nat Commun. 2016 Apr 19;7:11224. (PMID: 27091615)
Vaccine. 2009 Jun 12;27(29):3802-10. (PMID: 19446378)
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8175-9. (PMID: 8058775)
Infect Immun. 2004 May;72(5):2689-97. (PMID: 15102777)
Vaccine. 2001 Aug 14;19(31):4363-72. (PMID: 11483260)
Am J Respir Cell Mol Biol. 2009 Apr;40(4):474-81. (PMID: 18931326)
PLoS Pathog. 2013 Mar;9(3):e1003274. (PMID: 23555269)
Infect Immun. 2007 Mar;75(3):1196-202. (PMID: 17210665)
Vaccine. 2012 May 9;30(22):3304-10. (PMID: 22426326)
Microbes Infect. 2004 Nov;6(14):1241-9. (PMID: 15555529)
Int Rev Immunol. 2013 Jun;32(3):223-48. (PMID: 23617235)
Bioorg Khim. 1987 Feb;13(2):273-7. (PMID: 3580006)
J Biol Chem. 2002 Nov 1;277(44):41613-23. (PMID: 12196537)
Arch Immunol Ther Exp (Warsz). 1994;42(5-6):349-53. (PMID: 8572891)
Clin Diagn Lab Immunol. 1999 Jul;6(4):519-24. (PMID: 10391854)
Arch Immunol Ther Exp (Warsz). 1994;42(2):115-23. (PMID: 7503644)
ACS Infect Dis. 2020 Jul 10;6(7):1816-1826. (PMID: 32364376)
Eur J Immunol. 1993 May;23(5):1177-80. (PMID: 8477812)
Eur J Immunol. 2004 Dec;34(12):3346-58. (PMID: 15495164)
Br Med J (Clin Res Ed). 1985 Feb 16;290(6467):505-8. (PMID: 3918650)
Microbes Infect. 2007 Mar;9(3):251-8. (PMID: 17306586)
Eur J Immunol. 2007 Sep;37(9):2400-4. (PMID: 17683116)
Cell Mol Immunol. 2013 Jan;10(1):21-9. (PMID: 23085947)
Infect Immun. 2008 Jun;76(6):2678-84. (PMID: 18391006)
Front Immunol. 2012 Sep 11;3:281. (PMID: 22973276)
J Immunol. 2008 Jul 1;181(1):17-21. (PMID: 18566365)
Lancet. 2009 Sep 12;374(9693):893-902. (PMID: 19748398)
ACS Cent Sci. 2022 Apr 27;8(4):449-460. (PMID: 35559427)
Annu Rev Immunol. 2002;20:253-300. (PMID: 11861604)
PLoS One. 2013 Oct 25;8(10):e78611. (PMID: 24205278)
Drug Discov Today Technol. 2020 Dec;35-36:35-43. (PMID: 33388126)
Clin Diagn Lab Immunol. 2001 May;8(3):556-9. (PMID: 11329457)
Russ J Bioorg Chem. 2021;47(1):1-25. (PMID: 33776393)
Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4848-53. (PMID: 15781870)
Cell Chem Biol. 2016 Nov 17;23(11):1407-1416. (PMID: 27818299)
Ann N Y Acad Sci. 1992 May 4;651:44-58. (PMID: 1376060)
Clin Dev Immunol. 2013;2013:985753. (PMID: 23533458)
Infect Immun. 2003 Dec;71(12):6915-20. (PMID: 14638780)
Clin Infect Dis. 1996 Jun;22(6):973-81. (PMID: 8783696)
Hum Vaccin Immunother. 2015;11(9):2198-206. (PMID: 26176163)
Immunol Lett. 2002 Aug 1;83(1):61-6. (PMID: 12057856)
EMBO Mol Med. 2014 Jan;6(1):120-40. (PMID: 24408967)
J Immunol. 1992 Nov 15;149(10):3200-7. (PMID: 1431099)
PLoS Pathog. 2014 Oct 09;10(10):e1004300. (PMID: 25299581)
J Infect Dis. 2009 Sep 15;200(6):858-65. (PMID: 19656068)
J Med Microbiol. 2011 Jun;60(Pt 6):793-802. (PMID: 21393453)
Lancet. 2009 Oct 31;374(9700):1543-56. (PMID: 19880020)
Eur J Immunol. 2007 Dec;37(12):3404-13. (PMID: 18022862)
J Immunol. 2012 Feb 15;188(4):1708-16. (PMID: 22250090)
Microbes Infect. 2007 Mar;9(3):364-74. (PMID: 17314060)
Annu Rev Immunol. 1991;9:679-705. (PMID: 1832874)
J Pathol. 2007 May;212(1):29-37. (PMID: 17370296)
J Clin Immunol. 2017 May;37(4):388-396. (PMID: 28488145)
Eur J Immunol. 2008 Aug;38(8):2085-9. (PMID: 18624356)
Microb Drug Resist. 2010 Jun;16(2):135-42. (PMID: 20370508)
Indian J Med Res. 2004 May;119 Suppl:7-12. (PMID: 15232153)
Front Immunol. 2012 Dec 17;3:372. (PMID: 23251136)
Immunity. 2001 Jul;15(1):83-93. (PMID: 11485740)
J Infect Dis. 2001 Oct 15;184(8):1082-5. (PMID: 11574927)
Org Biomol Chem. 2023 Oct 25;21(41):8306-8319. (PMID: 37794804)
PLoS Pathog. 2008 Sep 19;4(9):e1000159. (PMID: 18802458)
Cell Chem Biol. 2016 Aug 18;23(8):1014-1022. (PMID: 27524293)
Am J Respir Crit Care Med. 2011 May 15;183(10):1391-401. (PMID: 21169470)
J Immunol. 2007 Apr 15;178(8):5271-6. (PMID: 17404311)
Infect Immun. 2010 Feb;78(2):764-72. (PMID: 19948836)
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001480. (PMID: 19370566)
Front Immunol. 2020 Dec 04;11:578019. (PMID: 33343566)
Eur J Immunol. 2012 Apr;42(4):982-92. (PMID: 22531922)
Nat Rev Immunol. 2013 Feb;13(2):88-100. (PMID: 23348415)
J Exp Med. 2008 Dec 22;205(13):3053-64. (PMID: 19075288)
Lancet. 2006 Mar 4;367(9512):740-8. (PMID: 16517274)
Curr Opin Immunol. 2010 Feb;22(1):34-40. (PMID: 20149616)
Lancet Infect Dis. 2014 Sep;14(9):839-46. (PMID: 25042756)
Vaccine. 2019 Jun 27;37(29):3840-3848. (PMID: 31153692)
J Immunol. 2011 Jan 1;186(1):432-42. (PMID: 21135172)
Hum Vaccin Immunother. 2016;12(2):336-43. (PMID: 26406267)
Science. 1989 May 26;244(4907):943-50. (PMID: 2658058)
Nat Rev Immunol. 2010 Jul;10(7):467-78. (PMID: 20539306)
Chem Rev. 2022 Oct 26;122(20):15672-15716. (PMID: 35608633)
Front Immunol. 2016 Apr 11;7:138. (PMID: 27148259)
BMC Infect Dis. 2004 Jun 30;4:21. (PMID: 15228629)
BMC Immunol. 2012 Jul 09;13:38. (PMID: 22776294)
Hum Vaccin Immunother. 2015;11(2):477-88. (PMID: 25692535)
Immunity. 2001 May;14(5):617-29. (PMID: 11371363)
PLoS Med. 2009 May 26;6(5):e1000081. (PMID: 19468297)
J Immunol. 2011 Jul 1;187(1):434-40. (PMID: 21646297)
J Clin Invest. 2009 Jul;119(7):1899-909. (PMID: 19509469)
Infect Immun. 2010 Feb;78(2):830-7. (PMID: 19995896)
Cell Mol Immunol. 2013 Jan;10(1):50-7. (PMID: 23064104)
Eur J Immunol. 2013 Sep;43(9):2317-26. (PMID: 23719868)
J Immunol. 2005 Feb 15;174(4):1787-90. (PMID: 15699104)
Cell Microbiol. 2012 Apr;14(4):460-6. (PMID: 22212419)
Chem Biol. 2014 Jan 16;21(1):38-50. (PMID: 24439205)
Glycoconj J. 2023 Apr;40(2):135-148. (PMID: 36652051)
فهرسة مساهمة: Keywords: B1 Cells; Streptococcus pneumoniae serotype 3; antibody; cytokine; interleukin 17A; mice immunoprotection; synthetic disaccharide; γδ T cells
المشرفين على المادة: 0 (Interleukin-17)
27432CM55Q (Serum Albumin, Bovine)
0 (Pneumococcal Vaccines)
0 (Disaccharides)
0 (Polysaccharides, Bacterial)
0 (Adjuvants, Immunologic)
0 (Antibodies, Bacterial)
0 (Il17a protein, mouse)
0 (Receptors, Antigen, T-Cell, gamma-delta)
تواريخ الأحداث: Date Created: 20240606 Date Completed: 20240606 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11150546
DOI: 10.3389/fimmu.2024.1388721
PMID: 38840926
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1388721